Jacobs Levy Equity Management, Inc Spectrum Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$0.43 - $1.56 $255,466 - $926,808	594,108 New	594,108 $255,000
Q2 2021 Aug 16, 2021	SELL	$2.89 - $4.45 $747,533 - $1.15 Million	-258,662 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.9 - $4.09 $1.53 Million - $2.16 Million	-527,593 Reduced 67.1%	258,662 $843,000
Q4 2020 Feb 16, 2021	SELL	$3.38 - $5.14 $1.06 Million - $1.61 Million	-313,440 Reduced 28.5%	786,255 $2.68 Million
Q3 2020 Nov 16, 2020	BUY	$2.99 - $4.9 $721,929 - $1.18 Million	241,448 Added 28.13%	1,099,695 $4.49 Million
Q2 2020 Aug 17, 2020	BUY	$2.11 - $3.38 $1.27 Million - $2.04 Million	602,162 Added 235.14%	858,247 $2.9 Million
Q1 2020 May 15, 2020	SELL	$1.83 - $3.45 $83,793 - $157,972	-45,789 Reduced 15.17%	256,085 $597,000
Q4 2019 Feb 14, 2020	BUY	$3.5 - $10.35 $1.06 Million - $3.12 Million	301,874 New	301,874 $1.1 Million
Q3 2017 Nov 14, 2017	SELL	$8.75 - $14.07 $1.03 Million - $1.66 Million	-117,647 Closed	0 $0
Q2 2017 Nov 09, 2017	BUY	N/A	117,647	117,647 $876,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.